A placebo-controlled, randomized, double-masked, variable dosage, clinical trial of azathioprine with and without methylprednisolone in multiple sclerosis.

@article{Ellison1989APR,
  title={A placebo-controlled, randomized, double-masked, variable dosage, clinical trial of azathioprine with and without methylprednisolone in multiple sclerosis.},
  author={Gaylord Ellison and L. W. Myers and Max R. Mickey and Michael C. Graves and Wallace W. Tourtellotte and Karl Syndulko and M I Holevoet-Howson and C D Lerner and M V Frane and P D Pettler-Jennings},
  journal={Neurology},
  year={1989},
  volume={39 8},
  pages={1018-26}
}
Ninety-eight patients with multiple sclerosis (MS) in the chronic progression phase entered a 3-year clinical trial to determine if azathioprine (AZ) alone or with adrenal cortical steroids stabilizes the course of MS. In group AM, the patients took AZ throughout and methylprednisolone (MP) for the first 36 weeks. Group AP received AZ and placebo instead of MP. Group PP took placebos for both drugs. We adjusted the AZ to maintain the total white blood cell count within 3,000 to 4,000/mm3; we… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 25 extracted citations

Similar Papers

Loading similar papers…